Chemical Structure (Alogliptin 01)
Alogliptin Tablet, Film Coated
Product Images NDC 63629-4946
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Alogliptin (NDC 63629-4946). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Alogliptin 02)
This appears to be a pharmaceutical document detailing the administration guidelines and interactions of the drug Alogliptin with other medications. It provides information on the dosage, frequency, and substrate properties of Alogliptin with various metabolic enzymes and transporters like CYP1A2, CYP2C8, CYP3A4, and Pgp. The document also includes details on coadministered drugs like Metformin, Cimetidine, Warfarin, Pioglitazone, Glyburide, and others with corresponding dosages and recommendations for dose adjustments.*
Figure 2 (Alogliptin 03)
This is a list of drugs being coadministered along with specific dosages and administration frequencies. The text explains interactions related to renal excretion, CYP enzymes inhibition, and P-glycoprotein (Pgp) effects. It includes drugs like metformin, cimetidine, gemfibrozil, pioglitazone, fluconazole, ketoconazole, atorvastatin, cyclosporine, digoxin, and alogliptin. The text also provides information on the ratio and 90% CI for drug combinations and states recommendations for dose adjustments.*
Figure 3 (Alogliptin 04)
This text appears to be a table showing baseline mean A1C values and LS mean change in A1C (%) for different treatments in a clinical study. The treatments mentioned are Placebo, Alogliptin, Pioglitazone, and the combination of Alogliptin and Pioglitazone. The data includes different dosages for Alogliptin and Pioglitazone. It also mentions that intent-to-treat population was used and includes a statistical significance comparison (*P<0.001) for the combination treatment compared to individual treatments.*
Figure 4 (Alogliptin 05)
This text provides statistical information comparing the drug NESINA (N) with a placebo (P) in terms of hazard ratio (HR) over a period of time in months from randomization. The hazard ratio is reported as 0.96 with a 98% confidence interval between 0.80 and 1.16. The number of individuals at risk for each group (N and P) at different time points is also included.*
Label (Lbl636294946)
This text is a pharmaceutical description of Alogliptin Benzoate, a medication with each film-coated tablet containing 25 mg of Alogliptin. It is recommended to store the tablets at 25°C, with allowable excursions between 15°C-30°C. The usual dosage instructions are provided on the package insert or via scanning the QR code. The tablets should be dispensed with a medication guide and the bottle should not be used if the seal is broken or missing. The manufacturer of the tablets is Bryant Ranch Prepack, Inc. under Takeda Pharmaceuticals USA.*
Figure (Logo)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
